Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Kumamoto, 861-4101, Japan.
Department of Radiology, Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan.
Sci Rep. 2021 Oct 8;11(1):20051. doi: 10.1038/s41598-021-99540-1.
There have been no report of objective clinical characteristics or prognostic factors that predict fatal outcome of acute respiratory distress syndrome (ARDS) since the Berlin definition was published. The aim of this study is to identify clinically available predictors that distinguish between two phenotypes of fatal ARDS due to pneumonia. In total, 104 cases of Japanese patients with pneumonia-induced ARDS were extracted from our prospectively collected database. Fatal cases were divided into early (< 7 days after diagnosis) and late (≥ 7 days) death groups, and clinical variables and prognostic factors were statistically evaluated. Of the 50 patients who died within 180 days, 18 (36%) and 32 (64%) were in the early (median 2 days, IQR [1, 5]) and late (median 16 days, IQR [13, 29]) death groups, respectively. According to multivariate regression analyses, the APACHE II score (HR 1.25, 95%CI 1.12-1.39, p < 0.001) and the disseminated intravascular coagulation score (HR 1.54, 95%CI 1.15-2.04, p = 0.003) were independent prognostic factors for early death. In contrast, late death was associated with high-resolution computed tomography (HRCT) score indicating early fibroproliferation (HR 1.28, 95%CI 1.13-1.42, p < 0.001) as well as the disseminated intravascular coagulation score (HR 1.24, 95%CI 1.01-1.52, p = 0.039). The extent of fibroproliferation on HRCT, and the APACHE II scores along with coagulation abnormalities, should be considered for use in predictive enrichment and personalized medicine for patients with ARDS due to pneumonia.
自柏林定义发布以来,尚无关于预测急性呼吸窘迫综合征(ARDS)致命结局的客观临床特征或预后因素的报道。本研究旨在确定可用于区分两种肺炎引起的致命性 ARDS 表型的临床可用预测因子。总共从我们前瞻性收集的数据库中提取了 104 例日本肺炎相关性 ARDS 患者。将致命病例分为早期(诊断后<7 天)和晚期(≥7 天)死亡组,并对临床变量和预后因素进行统计学评估。在 180 天内死亡的 50 例患者中,18 例(36%)和 32 例(64%)分别属于早期(中位数 2 天,IQR[1,5])和晚期(中位数 16 天,IQR[13,29])死亡组。根据多变量回归分析,APACHE II 评分(HR1.25,95%CI1.12-1.39,p<0.001)和弥散性血管内凝血评分(HR1.54,95%CI1.15-2.04,p=0.003)是早期死亡的独立预后因素。相反,晚期死亡与早期纤维化的高分辨率计算机断层扫描(HRCT)评分(HR1.28,95%CI1.13-1.42,p<0.001)以及弥散性血管内凝血评分(HR1.24,95%CI1.01-1.52,p=0.039)相关。HRCT 上纤维化的程度以及 APACHE II 评分和凝血异常,应考虑用于预测性富集和肺炎相关性 ARDS 患者的个体化治疗。